# Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

> **NCT01696058** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1137 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium
- **DRUG:** Placebo matching Olodaterol
- **DRUG:** Tiotropium
- **DRUG:** Olodaterol

## Key facts

- **NCT ID:** NCT01696058
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 1137 (ACTUAL)
- **Last updated:** 2014-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696058, "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01696058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*